Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816026 | 0.82 | OPRK1 (0.48) | OPRK1ALDH1A1ABL1NR4A2SLC6A4 | |
| SCHEMBL20872624 | 0.82 | OPRK1 (0.51) | OPRK1MAPK1KDM4ELMNA | |
| SCHEMBL473981 | 0.82 | OPRK1 (0.48) | OPRK1ALDH1A1ABL1NR4A2SLC6A4 | |
| SCHEMBL26930826 | 0.82 | CYP4F2 (0.46) | KDRALDH1A1MAPK1KDM4ELMNA | |
| SCHEMBL9119331 | 0.81 | ATM (0.47) | OPRK1ALDH1A1ABL1NR4A2MAPK1 | |
| SCHEMBL401530 | 0.81 | OPRK1 (0.47) | OPRK1ALDH1A1ABL1NR4A2SLC6A4 | |
| SCHEMBL18124622 | 0.80 | KDR (0.49) | KDRALDH1A1MAPK1KDM4ELMNA | |
| SCHEMBL4919152 | 0.80 | OPRK1 (0.44) | OPRK1ALDH1A1ABL1NR4A2SLC6A4 | |
| SCHEMBL22288713 | 0.79 | OPRK1 (0.46) | OPRK1ALDH1A1ABL1MAPK1KDM4E | |
| SCHEMBL21462378 | 0.79 | OPRK1 (0.46) | OPRK1ALDH1A1ABL1NR4A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4649086-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4622959-A1 | 2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | Merck Sharp & Dohme LLC (US) | 2025-10-01 | — | — | EP | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| CN-119325476-A | Nitrogen-containing condensed 2, 3-dihydroquinazolinone compounds as NAV1.8 inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2024-12-26 | — | — | US | disclosed |
| WO-2024151465-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023067546-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067546-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-04-27 | — | — | WO | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | KDR 2290/4885OPRK1 2566/4885ALDH1A1 1103/4885 |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | PRSS1, PRSS2, ACE2 | KDR 4402/4885OPRK1 1844/4885ALDH1A1 4236/4885 |
| US-20240425501-A1 | NOVEL BICYCLIC HETEROARYL DERIVATIVES AS SOS1:KRAS PROTEINPROTEIN INTERACTION INHIBITORS | KRAS, NRAS, SOS1 | KDR 2709/4885OPRK1 2664/4885ALDH1A1 3327/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | KDR 2018/4885OPRK1 302/4885ALDH1A1 2933/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | KDR 2290/4885OPRK1 2566/4885ALDH1A1 1103/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | KDR 2290/4885OPRK1 2566/4885ALDH1A1 1103/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | KDR 1973/4885OPRK1 2247/4885ALDH1A1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.